Trial Profile
A Phase 1a Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study Assessing Safety and Immunogenicity of Px563L and RPA563 Administered by Intramuscular Injection in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Sep 2021
Price :
$35
*
At a glance
- Drugs Px 563L (Primary) ; Monophosphoryl lipid A
- Indications Anthrax
- Focus Adverse reactions
- Sponsors Pfenex
- 17 Sep 2021 Results published in the Vaccine
- 07 Jul 2017 Status changed from active, no longer recruiting to completed.
- 08 Aug 2016 According to Pfenex media release, the company announced results from day 70 analysis of anthrax vaccine study .